Presenter revised presentation slides are available. Please contact Optivia for obtaining a copy.
Considerable progress has been made in understanding the role of efflux transporters in the ATP Binding Cassette Superfamily (ABC) in intestinal drug absorption and bioavailability. In marked contrast, much less progress has been made in intestinal influx transporters in the Solute Carrier Superfamily (SLC) that may play a role in drug absorption. In this webinar, I will describe recent studies from my laboratory and others suggesting important roles for three intestinal influx transporters in drug absorption: the thiamine transporter, THTR2 (SLC19A3), the organic cation transporter, OCT3, (SLC22A3) and the organic anion polypeptide, OATP2B1 (SLCO2B1). Experimental evidence indicating a role for these transporters will be described including in vitro substrate and inhibitor assays, high throughput fluorescent assays, and experiments in genetically engineered mice. Where possible links to clinical phenotypes will be presented. Collectively, the studies provide a body of evidence suggesting that influx transporters contribute to the absorption and bioavailability of prescription drugs and may be important mediators of drug-drug and drug-nutrient interactions.
Kathleen M. Giacomini, Ph.D.
Professor, University of California, San Francisco
Dr. Kathy Giacomini is Professor in the Department of Bioengineering and Therapeutic Sciences. She received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo and completed a post-doctoral fellowship at Stanford University. Dr. Giacomini is considered a leader in the field of pharmacogenomics of membrane transporters. Dr. Giacomini and her group discovered and functionally characterized over 100 transporter polymorphisms, identifying both gain of function and loss of function variants that may lead to variation in drug response. In genomewide association studies she and her team discovered genetic variants in transporters associated with response to the anti-diabetic drug, metformin and the anti-gout medication, allopurinol. Together with Dr. Russ Altman, she is the Co-Principal Investigator of the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (UCSF-Stanford CERSI), funded by the FDA. She has received numerous awards for her research and is an elected member of the National Academy of Medicine.
COI Statement: Dr. Kathy Giacomini declares that she is a co-founder of a biotech company, Apricity Therapeutics, Inc., which exploits transporters for safety and efficacy of anti-cancer drugs.
Organizer: Optivia Biotechnology Inc.
Time: Thu, April 20, 2017 10:00 AM - 11:30 AM PDT